clinical trial · NCT06188975
Expanded Access to ABBV-CLS-484
Advanced Solid Tumor CancerDRUG: ABBV-CLS-484
brief summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
started
—
primary completion
—
completion
—
last updated
Jan 3, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol